Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV.
about
Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.Human gene therapy and imaging in neurological diseases.Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potentialStriatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented.Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys.Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization propertiesPre-immunization with an intramuscular injection of AAV9-human erythropoietin vectors reduces the vector-mediated transduction following re-administration in rat brainSAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE.The influence of epileptic neuropathology and prior peripheral immunity on CNS transduction by rAAV2 and rAAV5.Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primatesViral vector-based reversible neuronal inactivation and behavioral manipulation in the macaque monkeyImmune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactionsDirect and retrograde transduction of nigral neurons with AAV6, 8, and 9 and intraneuronal persistence of viral particlesViral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.Gene therapy for misfolding protein diseases of the central nervous system.Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters.Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain.Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys.Gene therapy for Parkinson's disease: where are we now and where are we going?The advent of AAV9 expands applications for brain and spinal cord gene delivery.Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primatesNeutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.AAV-mediated delivery of optogenetic constructs to the macaque brain triggers humoral immune responses.Slow AAV2 clearance from the brain of nonhuman primates and anti-capsid immune response.Adeno-associated virus-mediated gene transfer of human aromatic L-amino acid decarboxylase protects mixed striatal primary cultures from L-DOPA toxicity.Gene transfer to the CNS is efficacious in immune-primed mice harboring physiologically relevant titers of anti-AAV antibodies.Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response.Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC.Anticonvulsant effects and behavioural outcomes of rAAV serotype 1 vector-mediated neuropeptide Y overexpression in rat hippocampus.Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene TransferGene therapy for Parkinson's disease
P2860
Q30531601-8D1B3FA1-281C-46D5-A266-DED295500BB4Q31023442-952151FE-2FAD-4683-BFE6-CB93631F7987Q33374015-93B090B4-43E4-4D96-BFE7-F3A998ABB72AQ33713348-7F993FCF-C4A7-42A8-B87C-E05C7324A149Q33819946-6610859B-9468-4941-9F87-E9D873C2C341Q34228552-8ABF6D73-C82A-4D16-8BCC-7E4A9CF7311AQ34718452-3E835E0E-D4C1-4A62-A586-F406AD6CC359Q34762396-A7218A44-4798-4A0C-9CB8-0F0E0110593DQ35341751-05E65CBF-8DA9-4059-A5D8-6CDA54D1CF3CQ35892068-D86B6069-2BC8-401D-899E-7F97E077B275Q36041623-9360859C-A473-4B6E-A2D4-96C0A98B4517Q36498773-9618A026-ECDE-4AA7-95AA-473D7CEF5E80Q36945745-B9431722-4C5D-490E-B8DB-09E0671B8754Q36960666-E9199796-144D-4853-9BE2-D4F562CFB4A0Q36983203-ABE9FE87-AFD3-4710-8886-6489140060DCQ37127238-F1D9352C-F1E3-4362-9D17-2B37DFA3F542Q37275446-04A409E9-2318-4670-ACDC-AD6D6D3B7758Q37398172-A97DDF01-1F82-47FD-96F1-A753873CC694Q37399627-0C84C098-A627-4441-A75D-58D684723A98Q37810994-FFF9D5A5-17DD-4A05-8779-267334758E96Q38004089-7E27581C-CC68-4A39-8947-3EFF09191DC1Q38949089-84ACC5D4-D07C-4AFC-8921-975E6F5E0365Q39076892-5285A86F-C22E-4D9F-B38E-17F24C40D577Q39519818-4660C973-E790-4646-9137-5959B45846BDQ40334450-F8204230-F313-4B42-8B68-E7F184A79440Q40383175-9ACB310D-4768-46D8-9ED8-94651B20E61DQ40433968-9C59A277-52BC-43F4-B60D-38EA90767DACQ41785441-97053D4B-C70E-4878-8345-51D63A683AC8Q42450986-C63ECE34-FB0D-4373-BE99-3CA72655A570Q42502571-09AB4FB8-BEDB-4C0A-AD44-90535B12E1FEQ43134453-695657A9-E96C-4F44-8C1C-0175F3E0F1F3Q58584630-4F708F75-D2F6-4725-9200-B6A9F9FD63AAQ58913419-4028805D-D137-46AB-AD1C-0380991496B8
P2860
Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV.
@en
type
label
Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV.
@en
prefLabel
Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV.
@en
P2093
P1433
P1476
Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV.
@en
P2093
Brian M Suzuki
Janet Cunningham
John R Forsayeth
Laura M Sanftner
Mohammad M Doroudchi
P304
P356
10.1016/J.YMTHE.2003.12.005
P577
2004-03-01T00:00:00Z